Aurobindo Pharma Limited said, the company’s unit - IX, Sangareddy District, inspected by the United States Food and Drug Administration (US FDA) from November 10 to November 18, 2022, has now been classified as Voluntary Action Indicated (VAI), via an exchange filing.
The unit is an API intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana.
The disclosure is pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
